News

Lilly pill cuts body weight by 12.4% in trial, lagging Novo's Wegovy injection
Eli Lilly said on Thursday that its experimental GLP-1 pill helped patients lose 12.4% of their body weight in a late-stage study, but that was less than previous trial results for Novo Nordisk's ...
Eli Lilly beats earnings for second quarter on strong GLP-1 sales, stock dives on GLP-1 pill trial results
Eli Lilly reported second quarter earnings Thursday, a day after competitor Novo Nordisk missed earnings estimates by Wall ...
Eli Lilly's Rare Weight Loss Data Miss Could Benefit Competitors
On Thursday, Eli Lilly and Co.’s (NYSE:LLY) weight loss rival Novo Nordisk A/S (NYSE:NVO), along with smaller firms, Terns Pharmaceuticals, Inc. (NASDAQ:TERN), Viking Therapeutics Inc. (NASDAQ:VKTX), ...
Eli Lilly shares tumble over 10% after disappointing weight-loss pill data
Lilly’s results from an obesity pill study didn’t perform as well as Wall Street expected. It resulted in lower weight loss ...
Eli Lilly Weight-Loss Pill Trial Disappoints, Offsetting Solid Profit and Sales
Key Takeaways Results from a late-stage trial of Eli Lilly's experimental weight loss pill were disappointing, sending shares of the drugmaker tumbling.The study found average weight loss from the ...